Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of 3'UTRMYCN M1-14 in MYCN-driven pediatric and adult cancers
PACTR202607461619486Phase 1Not yet recruiting
- Sponsor
- UTR Therapeutics
- Start
- Jan 2027
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTRxMYCN M1-14 in rhabdomyosarcoma (RMS), neuroblastoma, retinoblastoma (Rb) and 12 more, sponsored by UTR Therapeutics. Primary endpoints: Safety and tolerability and Maximum tolerated dose and recommended phase 2 dose. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
UTRxMYCN M1-14
03
Conditions
rhabdomyosarcoma (RMS)neuroblastomaretinoblastoma (Rb)Wilms' tumormedulloblastoma
Beyond the preview
Go deeper on PACTR202607461619486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607461619486.